What is the role of direct hemoperfusion-type adsorption column (Lixelle) in beta-2-microglobulin (beta-2m) amyloidosis prevention?

Updated: Nov 14, 2019
  • Author: Anita Basu, MD, FACP; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

This was developed to selectively eliminate beta-2m from the circulating blood of patients with DRA. Lixelle treatments reduce the circulating levels of beta-2m and inflammatory cytokines, thereby improving the symptoms of patients with DRA. While this therapy has been used and studied in Japan, it is not currently employed in the United States. [24, 26]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!